Pharmacological advances in the prevention of contrast-induced renal damage: a critical review
DOI:
https://doi.org/10.62452/jcrfnb08Keywords:
Nephroprotection, Iodinated contrast, acute renal damage, pharmacological therapies, renal failureAbstract
Contrast-induced nephropathy (CIN) is a common complication linked to diagnostic and therapeutic procedures involving iodinated contrast agents. It represents a major cause of hospital-acquired acute kidney injury, particularly among patients with comorbidities such as diabetes mellitus and chronic kidney disease. This critical review explores recent advances in pharmacological nephroprotective strategies, including the use of antioxidants, selective vasodilators, and chelating agents. The efficacy of N-acetylcysteine, statins, SGLT2 inhibitors, and alkaline solutions such as sodium bicarbonate is highlighted. Despite growing research interest, existing evidence remains heterogeneous, underlining the urgent need for standardized multicenter trials. This analysis provides a comprehensive overview of the current therapeutic landscape and proposes future research directions aimed at optimizing renal protection in high-risk clinical settings.
Downloads
References
Chaudhari, H., Mahendrakar, S., Baskin, S. E., & Reddi, A. S. (2022). Contrast-induced acute kidney injury: Evidence in support of its existence and a review of its pathogenesis and management. International Journal of Nephrology and Renovascular Disease, 15, 253–266. https://doi.org/10.2147/IJNRD.S371700
Cheng, A. S., & Li, X. (2023). The potential biotherapeutic targets of contrast-induced acute kidney injury. International Journal of Molecular Sciences, 24(9), 8254. https://doi.org/10.3390/ijms24098254
Ehrmann, S., Aronson, D., & Hinson, J. S. (2018). Contrast-associated acute kidney injury is a myth: Yes. Intensive Care Medicine, 44(1), 104–106. https://doi.org/10.1007/s00134-017-4950-6
Hall, J., & Hall, M. (2021). Medical physiology (14.a ed.). Elsevier.
Johnson, R., Feehally, J., & Floege, J. (2014). Comprehensive clinical nephrology (5.a ed.). Elsevier.
Khwaja, A. (2012). KDIGO clinical practice guidelines for acute kidney injury. Nephron Clinical Practice, 120(4), 179–184. https://doi.org/10.1159/000339789
Kusirisin, P., Chattipakorn, S. C., & Chattipakorn, N. (2020). Contrast-induced nephropathy and oxidative stress: Mechanistic insights for better interventional approaches. Journal of Translational Medicine, 18(1), 400. https://doi.org/10.1186/s12967-020-02574-8
Li, Y., & Wang, J. (2024). Contrast-induced acute kidney injury: A review of definition, pathogenesis, risk factors, prevention and treatment. BMC Nephrology, 25(1), 140. https://doi.org/10.1186/s12882-024-03570-6
McCullough, P. A., & Soman, S. S. (2005). Contrast-induced nephropathy. Critical Care Clinics, 21(2), 261–280. https://doi.org/10.1016/j.ccc.2004.12.003
Mo, E., Ebedy, Y. A., Ibrahim, M. A., Farroh, K. Y., & Hassanen, E. I. (2022). Newly synthesized chitosan-nanoparticles attenuate carbendazim hepatorenal toxicity in rats via activation of Nrf2/HO1 signalling pathway. Scientific Reports, 12(1), 9986. https://www.nature.com/articles/s41598-022-13960-1
Mohammed, N. M. A., Mahfouz, A., Achkar, K., Rafie, I. M., & Hajar, R. (2013). Contrast-induced nephropathy. Heart Views, 14(3), 106–116. https://doi.org/10.4103/1995-705X.125926
Ogobuiro, I., & Tuma, F. (2023). Physiology, renal. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK538339/
Ozkok, S., & Ozkok, A. (2017). Contrast-induced acute kidney injury: A review of practical points. World Journal of Nephrology, 6(3), 86–99. https://doi.org/10.5527/wjn.v6.i3.86
Pattharanitima, P., & Tasanarong, A. (2014). Pharmacological strategies to prevent contrast-induced acute kidney injury. BioMed Research International, 2014, 236930. https://doi.org/10.1155/2014/236930
Ramachandran, P., & Jayakumar, D. (2020). Contrast-induced acute kidney injury. Indian Journal of Critical Care Medicine, 24(S3), 122–125. https://doi.org/10.5005/jp-journals-10071-23379
Seeliger, E., Sendeski, M., Rihal, C. S., & Persson, P. B. (2012). Contrast-induced kidney injury: Mechanisms, risk factors, and prevention. European Heart Journal, 33(16), 2007–2015. https://doi.org/10.1093/eurheartj/ehr494
Tortora, J., & Derrickson, B. (2018). Principios de anatomía y fisiología (15.a ed.). Médica Panamericana.
Ul Haq, M. F., Yip, C. S., & Arora, P. (2020). The conundrum of contrast-induced acute kidney injury. Journal of Thoracic Disease, 12(4), 1721–1727. https://doi.org/10.21037/jtd.2019.12.88
Wu, T., Zhu, W., Duan, R., Sun, J., Bao, S., Chen, K., Han, B., Chen, Y., & Lu, Y. (2024). Magnetic vagus nerve stimulation ameliorates contrast-induced acute kidney injury by circulating plasma exosomal miR-365-3p. Journal of Nanobiotechnology, 22(1), 666. https://doi.org/10.1186/s12951-024-02928-0
Xue, X., Bo, R., Qu, H., Jia, B., Xiao, W., Yuan, Y., Vapniarsky, N., Lindstrom, A., Wu, H., Zhang, D., Li, L., Ricci, M., Ma, Z., Zhu, Z., Lin, T., Louie, A. Y., & Li, Y. (2020). A nephrotoxicity-free, iron-based contrast agent for magnetic resonance imaging of tumors. Biomaterials, 257, 120234. https://doi.org/10.1016/j.biomaterials.2020.120234
Yan, S.-X., Gao, M., Yang, T.-H., Tian, C., & Jin, S. (2022). The preventive effects of different doses of atorvastatin on contrast-induced acute kidney injury after CT perfusion. Journal of Clinical Laboratory Analysis, 36(7), e24386. https://doi.org/10.1002/jcla.24386
Yat Wong, P. C., Li, Z., Guo, J., & Zhang, A. (2012). Pathophysiology of contrast-induced nephropathy. International Journal of Cardiology, 158(2), 186–192. https://doi.org/10.1016/j.ijcard.2011.06.115
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Alex Ramón Valencia-Herrera, Kevin Abel Alvear-Arroyo, Frank Joel Lemache-Mancheno (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish in Revista Metropolitana de Ciencias Aplicadas (REMCA), agree to the following terms:
1. Copyright
Authors retain unrestricted copyright to their work. Authors grant the journal the right of first publication. To this end, they assign the journal non-exclusive exploitation rights (reproduction, distribution, public communication, and transformation). Authors may enter into additional agreements for the non-exclusive distribution of the version of the work published in the journal, provided that acknowledgment of its initial publication in this journal is given.
© The authors.
2. License
The articles are published in the journal under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0). The terms can be found at: https://creativecommons.org/licenses/by-nc-sa/4.0/deed.en
This license allows:
- Sharing: Copying and redistributing the material in any medium or format.
- Adapting: Remixing, transforming, and building upon the material.
Under the following terms:
- Attribution: You must give appropriate credit, provide a link to the license, and indicate if any changes were made. You may do this in any reasonable manner, but not in any way that suggests the licensor endorses or sponsors your use.
- NonCommercial: You may not use the material for commercial purposes.
- ShareAlike: If you remix, transform, or build upon the material, you must distribute your creation under the same license as the original work.
There are no additional restrictions. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
